Kestra Medical Technologies’ (KMTS) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report issued on Wednesday,Benzinga reports. BTIG Research currently has a $32.00 price objective on the stock.

A number of other equities analysts also recently issued reports on KMTS. Piper Sandler lifted their price target on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday. Wells Fargo & Company lifted their target price on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price target on Kestra Medical Technologies in a report on Friday, January 16th. Finally, Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a research report on Friday, December 12th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Kestra Medical Technologies Stock Performance

KMTS opened at $20.58 on Wednesday. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a market cap of $1.20 billion and a price-to-earnings ratio of -5.20. The company’s fifty day moving average price is $23.80 and its two-hundred day moving average price is $24.65. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm’s revenue was up 62.7% compared to the same quarter last year.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the sale, the insider directly owned 364,786 shares of the company’s stock, valued at $7,394,212.22. This trade represents a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Traci S. Umberger sold 10,500 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total value of $280,245.00. Following the transaction, the insider directly owned 136,633 shares in the company, valued at $3,646,734.77. This represents a 7.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 70,500 shares of company stock valued at $1,709,145. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. raised its holdings in Kestra Medical Technologies by 32.4% during the 2nd quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock valued at $7,318,000 after acquiring an additional 108,103 shares during the period. Brown Advisory Inc. boosted its holdings in shares of Kestra Medical Technologies by 5.4% in the second quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after acquiring an additional 29,607 shares during the period. Eventide Asset Management LLC grew its position in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after purchasing an additional 785,557 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Kestra Medical Technologies during the 2nd quarter valued at $54,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $562,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.